Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(60%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Active, not recruiting1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

active_not_recruiting120%
recruiting240%
terminated120%
completed120%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT05601440
recruitingphase_1

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT04855656
completedphase_2

RP-6306 in Patients With Advanced Cancer

NCT05605509
active_not_recruitingphase_1

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

NCT05566574
terminatedphase_1

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309

Clinical Trials (5)

Showing 5 of 5 trials
NCT05601440Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
NCT04855656Phase 1

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Recruiting
NCT05605509Phase 2

RP-6306 in Patients With Advanced Cancer

Completed
NCT05566574Phase 1

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Active Not Recruiting
NCT05405309Phase 1

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5